Protocol # STERIO-SCD, A Phase lib Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients with Sickle Cell Diseases
03/20/2018 - 09/19/2019 (Co-PI)
PI: Elizabeth S. Klings, MD
University of Pittsburgh Bayer HealthCare

05/16/2017 - 05/16/2019 (PI)
Pfizer, Inc

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Perrine SP, Ghalie RG. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov; 88(11):E255-60.View Related Profiles. PMID: 23828223; DOI: 10.1002/ajh.23533;.
  2. Andersson BA, Wering ME, Luo HY, Basran RK, Steinberg MH, Smith HP, Chui DH. Sickle cell disease due to compound heterozygosity for Hb S and a novel 7.7-kb beta-globin gene deletion. Eur J Haematol. 2007 Jan; 78(1):82-5.View Related Profiles. PMID: 17038017.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Contact for Mentoring: